2. Search Result
Search Result
Pathways Recommended: Metabolic Enzyme/Protease
Results for "

metabolic dysfunction

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

2

Screening Libraries

1

Biochemical Assay Reagents

2

Peptides

6

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-59291
    Levacetylleucine

    N-Acetyl-L-leucine

    		 Amino Acid Derivatives Neurological Disease Metabolic Disease Inflammation/Immunology
    Levacetylleucine (N-acetyl-L-leucine), an orally bioavailable and brain-penetrant compound, is an acetylated derivative of amino acid Leucine. Levacetylleucine is the active form of N-acetyl-leucine (NAL). Levacetylleucine attenuates neuronal death and neuroinflammation in the cortical tissue of mice. Levacetylleucine also potentially improves ameliorates lysosomal and metabolic dysfunction. Levacetylleucine improves compensation of postural symptoms after unilateral chemical labyrinthectomy (UL) in rats. Levacetylleucine is promising for research of neurological manifestations of Niemann-Pick disease type C, traumatic brain injury and neurodegeneration prevention .
    Levacetylleucine
  • HY-172317
    AZD2389

    		FAP Metabolic Disease
    AZD2389 is a potent and orally active FAP inhibitor. AZD2389 can be used for the study of metabolic dysfunction-associated steatohepatitis .
    AZD2389
  • HY-N0035
    Arctigenin
    Maximum Cited Publications
    8 Publications Verification

    (-)-Arctigenin

    		 MMP Influenza Virus Autophagy Apoptosis Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Arctigenin ((-)-Arctigenin), a biologically active lignan, can be used as an antitumor agent. Arctigenin exhibits potent antioxidant, anti-inflammatory and antiviral (influenza A virus) activities. Arctigenin can be used for the research of metabolic disorders, and central nervous system dysfunctions .
    Arctigenin
  • HY-156681A
    (S)-STX-478

    		PI3K Cancer
    (S)-STX-478 is the S-enantiomer of STX-478. STX-478 is a selective inhibitor of PI3Kα mutants, preventing metabolic dysfunction and demonstrating antitumor activity in xenograft mouse models with PI3Kα mutant tumors .
    (S)-STX-478
  • HY-163032
    FABP4-IN-3

    		FABP Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    FABP4-IN-3 (compound C3) is a highly selective FABP4 inhibitor (FABP4 Ki = 25 ± 3 a nM, FABP3 Ki = 15.03 μM) which exhibits a 601-fold selectivity over FABP3. FABP4-IN-3 also shows metabolic stability and potent cellular anti-inflammatory activity, making it promising to get involved in the research of metabolic disease, cardiac dysfunction and inflammation-related disease .
    FABP4-IN-3
  • HY-160168
    BTK-IN-31

    		Btk Infection Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    BTK-IN-31 (Compound 2) is a selective, non-covalently reversible, and blood-brain barrier (BBB) permeable Btk inhibitor. BTK-IN-31 has research potential in immune disorders, cancer, cardiovascular disease, viral infections, inflammation, metabolic/endocrine dysfunction, and neurological disorders .
    BTK-IN-31
  • HY-161279
    Antibiofilm agent-5

    		Bacterial Lactate Dehydrogenase Reactive Oxygen Species (ROS) Infection
    Antibiofilm agent-5 (compound 6c) is a multitargeting antibacterial agent with potent antibiofilm activity. Antibiofilm agent-5 could induce metabolic dysfunction by deactivating lactate dehydrogenase and promote the accumulation of reactive oxygen species to decrease the reduced glutathione and ultimately cause oxidative damage in bacteria. Antibiofilm agent-5 can be used for the research of refractory biofilm-intensified bacterial infections .
    Antibiofilm agent-5
  • HY-173265
    CypB-IN-1

    		Cyclophilin Metabolic Disease Inflammation/Immunology
    CypB-IN-1 (Compound 11) is an inhibitor of cyclophilin B (cyclophilin B) with a Kd value of 12 nM. CypB-IN-1 can be applied to the research field of metabolic dysfunction-associated steatohepatitis (MASH) and the liver fibrosis diseases resulting from it .
    CypB-IN-1
  • HY-159881
    SHS206

    		Mitophagy Metabolic Disease
    SHS206 (compound 6n) is an orally active mitochondrial uncoupler that reduces hepatic triglyceride levels. SHS206 exhibits in vivo efficacy in the GAN mouse model and shows inhibitory effects on metabolic dysfunction-associated steatohepatitis (MASH) .
    SHS206
  • HY-162122
    PPARα/γ agonist 3

    		PPAR Inflammation/Immunology
    PPARα/γ agonist 3 (Compound 4) is a dual agonist of PPARα/γ. PPARα/γ agonist 3 has anti-inflammatory activity, significantly reducing inflammatory markers such as IL-6 and MCP-1 on THP-1 macrophages through NF-κB activation. PPARα/γ agonist 3 can be used in the study of metabolic syndrome and metabolic dysfunction-related fatty liver disease (MAFLD) .
    PPARα/γ agonist 3
  • HY-168629
    FXR agonist 9

    		FXR Metabolic Disease
    FXR agonist 9 (compound 26) is an oral active and selectivity FXR partial agonist with the EC50 of 0.09 µM (75.13 % maximum efficacy). FXR agonist 9 ameliorates pathological features in HFD and CCl4(HY-Y0298)-induced metabolic dysfunction-associated steatohepatitis mice .
    FXR agonist 9
  • HY-N8423
    α-Amyrin
    1 Publications Verification

    		 ERK GSK-3 Neurological Disease Metabolic Disease
    α-Amyrin is a pentacyclic triterpenoid compound with oral activity. α-Amyrin activates the ERK and GSK-3β signaling pathways. α-Amyrin can be used in the study of metabolic syndrome induced by high fructose diet and cognitive dysfunction caused by low cholinergic neurotransmission .
    α-Amyrin
  • HY-168046
    ALG-055009

    		Thyroid Hormone Receptor Metabolic Disease
    ALG-055009 is a thyroid hormone receptor β (THR-β) agonist with an EC50 value of 0.063 μM. In rats on a high-fat diet, ALG-055009 can lower total cholesterol levels. ALG-055009 can be used in studies related to metabolic dysfunction-associated fatty liver disease .
    ALG-055009
  • HY-N0035R
    Arctigenin (Standard)

    (-)-Arctigenin (Standard)

    		 Reference Standards MMP Influenza Virus Autophagy Apoptosis Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Arctigenin (Standard) is the analytical standard of Arctigenin. This product is intended for research and analytical applications. Arctigenin ((-)-Arctigenin), a biologically active lignan, can be used as an antitumor agent. Arctigenin exhibits potent antioxidant, anti-inflammatory and antiviral (influenza A virus) activities. Arctigenin can be used for the research of metabolic disorders, and central nervous system dysfunctions .
    Arctigenin (Standard)
  • HY-172122
    FXR/HSD17B13 modulator 1

    		FXR 17β-HSD Metabolic Disease
    FXR/HSD17B13 modulator 1 (compound 6) is a potent modulator of FXR/HSD17B13. FXR/HSD17B13 modulator 1 plays an important roel in metabolic dysfunction-associated steatohepatitis (MASH) research .
    FXR/HSD17B13 modulator 1
  • HY-170369
    SHO1122147

    		Mitochondrial Metabolism Metabolic Disease
    SHO1122147 (Compound 7m) affects the mitochondrial electron transport chain, exhibits mitochondrial uncoupling activity (EC50=3.6 μM), and increases the oxygen consumption rate (OCR=69%) and promotes cellular respiration. SHO1122147 is orally active, and can be used in reaearch of obesity and metabolic dysfunction-associated steatohepatitis (MASH) .
    SHO1122147
  • HY-122706A
    IP6K2-IN-2

    		IPK Superfamily Metabolic Disease
    IP6K2-IN-2 (Compound 6) is an IP6K2 inhibitor, with IC50 values of 0.58 μM (IP6K2), 0.86 μM (IP6K1) and 3.08 μM (IP6K3). IP6K2-IN-2 can be used in research of obesity .
    IP6K2-IN-2
  • HY-125863B
    Glucose 6-phosphate dehydrogenase (yeast, recombinant)

    G6PD (yeast, recombinant)

    		 Endogenous Metabolite Cardiovascular Disease Metabolic Disease Cancer
    Glucose 6-phosphate dehydrogenase (yeast, recombinant) is the rate-limiting enzyme of the pentose phosphate pathway and a major source of NADPH in antioxidant pathways, nitric oxide synthase, NADPH oxidase, and cytochrome P450 systems. Glucose 6-phosphate dehydrogenase helps cells resist oxidative stress and regulates metabolic rates. It holds potential for research in fields such as diabetes, endothelial dysfunction, cancer, and cardiomyopathy .
    Glucose 6-phosphate dehydrogenase (yeast, recombinant)
  • HY-171454
    DA-1241

    		GPR119 Metabolic Disease Inflammation/Immunology
    DA-1241 is a GPR119 agonist. DA-1241 reduces macrophage differentiation through downregulation of NFκB signaling by activating GPR119. DA-1241, alone and in combination with a DPP4 inhibitor, reduces liver inflammation and restores inflammation-related liver gene expression. DA-1241 can be used for the research of metabolic dysfunction-associated steatohepatitis (MASH) .
    DA-1241
  • HY-168713
    LZ-007

    		FXR Metabolic Disease
    LZ-007 is an agonist for farnesoid X receptor (FXR) with an EC50 of 51 nM measuring by TR-FRET assay, or an EC50 of 76 nM in HepG2 cell. LZ-007 exhibits good pharmacokinetic characheristics in SD rats. LZ-007 ameliorates western diet and CCl4 (HY-Y0298)-induced mice metabolic dysfunction-associated steatohepatitis
    LZ-007
  • HY-137899
    Dephospho-CoA
    1 Publications Verification

    		 Endogenous Metabolite Metabolic Disease Cancer
    Dephospho-CoA is a key intermediate in the biosynthesis of coenzyme A (CoA), which is catalyzed by GTP-dependent dephospho-CoA kinase (DPCK) to generate CoA. Dephospho-CoA completes the final synthesis step of CoA through phosphorylation reaction and participates in energy metabolism and cell signaling. Dephospho-CoA can be used in research including cancer (such as regulating cell proliferation) and metabolic diseases (such as mitochondrial dysfunction) .
    Dephospho-CoA
  • HY-N8423R
    α-Amyrin (Standard)

    		Reference Standards ERK GSK-3 Neurological Disease Metabolic Disease
    α-Amyrin (Standard) is the analytical standard of α-Amyrin. This product is intended for research and analytical applications. α-Amyrin is a pentacyclic triterpenoid compound with oral activity. α-Amyrin activates the ERK and GSK-3β signaling pathways. α-Amyrin can be used in the study of metabolic syndrome induced by high fructose diet and cognitive dysfunction caused by low cholinergic neurotransmission .
    α-Amyrin (Standard)
  • HY-P11208
    mNLS-CPP-WSTF

    		GABA Receptor Inflammation/Immunology
    mNLS-CPP-WSTF is a nuclear localization signal (NLS)-cell-penetrating peptide based on the mouse WSTF sequence. mNLS-CPP-WSTF significantly inhibits the GABARAP-WSTF interaction, WSTF degradation and inflammatory gene expression. mNLS-CPP-WSTF effectively attenuates chronic inflammation, liver fibrosis and cartilage damage in metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA) mice model. mNLS-CPP-WSTF is promising for research of chronic inflammatory diseases such as MASH and OA .
    mNLS-CPP-WSTF
  • HY-159120
    ZG-2291

    		HIF/HIF Prolyl-Hydroxylase Metabolic Disease
    ZG-2291 is a selective inhibitor targeting FIH (Factor Inhibiting HIF) with oral activity. By binding to FIH, ZG-2291 promotes a conformational flip of a catalytically important tyrosine, enabling selective inhibition of FIH without affecting other 2OG oxygenases in the JmjC subfamily. ZG-2291k enhances thermogenesis in ob/ob mice and improves obesity-related symptoms and metabolic dysfunctions. ZG-2291 holds promise for research in the field of obesity-related diseases .
    ZG-2291
  • HY-174887
    THR-β agonist 9

    		Thyroid Hormone Receptor AMPK Acetyl-CoA Carboxylase Mitochondrial Metabolism Metabolic Disease
    THR-β agonist 9 is a potent, selective, and His435 mutation-sensitive THR-β (EC50: 3.2 nM) agonist. THR-β agonist 9 has moderate selectivity (approximately 10-fold) and good activation capacity (EC50: 134.2 nM to 515.5 nM) for multiple His435 mutants (H435A, H435Y, and H435R). THR-β agonist 9 has the potential to be used in the study of dyslipidemia, metabolic dysfunction-associated steatohepatitis (MASH), or resistance to thyroid hormone (RTH) .
    THR-β agonist 9
  • HY-158766
    3-sucCA

    3-Succinylated cholic acid

    		 Endogenous Metabolite Bacterial Infection Inflammation/Immunology
    3-sucCA is an orally available bacterial bile acid that exerts anti-MASH effects by promoting the growth of Akkermansia muciniphila. By remodeling the intestinal microbiota and promoting the growth of Akkermansia, 3-sucCA can improve intestinal barrier damage and reduce chronic low-level inflammation, thereby alleviating the progression of metabolic dysfunction-associated steatohepatitis (MASH). 3-sucCA accelerates the synthesis of cell wall peptidoglycan and has in vivo efficacy in the mouse MAFL-MASH model. 3-sucCA levels are low in the MAFLD model and are mainly used in the study of MASH .
    3-sucCA
  • HY-176214
    PPARγ agonist 19

    		PPAR COX Metabolic Disease
    PPARγ agonist 19 (Compound 5e) is a PPARγ agonist. PPARγ agonist 19 has an IC50 of 11.27 μM against COX-1 and an IC50 of 0.05 μM against COX-1. PPARγ agonist 19 increases glucose uptake in rat hemidiaphragm assay and is superior to pioglitazone (HY-13956). PPARγ agonist 19 alleviates hyperglycemia and insulin resistance in an in vivo model of type 2 diabetes in rats and protects against renal and lipidemia damage caused by metabolic dysfunction .
    PPARγ agonist 19
  • HY-W250122
    Glutamic acid sodium salt

    Monosodium glutamate

    		 Biochemical Assay Reagents Reactive Oxygen Species (ROS) Mitochondrial Metabolism Apoptosis HSP Bcl-2 Family Neurological Disease Metabolic Disease Inflammation/Immunology
    Glutamic acid sodium salt (Monosodium glutamate) is an orally active food flavor enhancer. Glutamic acid sodium salt causes ROS generation, mitochondrial dysfunction, and Apoptosis. Glutamic acid sodium salt upregulates CHOP, Grp78, and Bcl-2. Glutamic acid sodium salt impairs cognition, induces depressive-like behavior, induces hyperalgesia, and induces obesity and insulin resistance. Glutamic acid sodium salt can be used to study neurotoxicity (e.g., brain damage, cognitive impairment), metabolic disorders (e.g., obesity, insulin resistance), hepatotoxicity, and renal toxicity, as well as pain-related disorders .
    Glutamic acid sodium salt
  • HY-172883
    ABP/PPAR modulator 1

    		FABP PPAR Metabolic Disease Inflammation/Immunology
    ABP/PPAR modulator 1 is an orally active FABP and PPAR multiple modulator (IC50s of 0.65  μM and 1.08  μM for FABP1 and FABP4, EC50 s of 9.19  μM, 2.20  μM and 1.58 μM for PPARα, PPARγ and PPARδ). ABP/PPAR modulator 1 has potent anti-metabolic dysfunction-associated steatohepatitis (MASH) activity. ABP/PPAR modulator 1 dose-dependently ameliorates multiple pathological characteristics of fatty liver in WD + Carbon tetrachloride-induced MASH mice model .
    ABP/PPAR modulator 1
  • HY-174133
    HSD17B13-IN-104

    		17β-HSD Metabolic Disease Inflammation/Immunology
    HSD17B13-IN-104 (Compound 32) is an orally active, highly potent and selective HSD17B13 inhibitor (IC50=2.5 nM). HSD17B13-IN-104 regulates hepatic lipid metabolism by inhibiting the SREBP-1c/FAS pathway. HSD17B13-IN-104 blocks HSD17B13 enzymatic activity to improve hepatic lipid accumulation. HSD17B13-IN-104 is promising for research of metabolic dysfunction-associated steatohepatitis .
    HSD17B13-IN-104
  • HY-172661
    Kylo-0603

    		Thyroid Hormone Receptor Interleukin Related LDLR Infection Metabolic Disease
    KYLO-0603 is an orally active, selective THR-β agonist (EC50: 31.07 nM). KYLO-0603 has significant activity in lowering serum cholesterol and low-density lipoprotein cholesterol. KYLO-0603 upregulates the expression of THR-regulated genes (including iodothyronine deiodinase 1 (Dio1), malic enzyme 1 (Me1), and thyroid hormone response (Thrsp) gene) and inhibits the expression of inflammatory and fibrotic genes (low-density lipoprotein receptor (LDL-R) gene) by activating THR-β receptors. KYLO-0603 can be used to treat metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis research .
    Kylo-0603
  • HY-174306
    MARY1

    		5-HT Receptor PGC-1α Akt PI3K Ras MEK ERK Metabolic Disease
    MARY1 is a selective 5-HT2BR antagonist with an IC50 of 380 nM and a Ki of 764 nM (human 5-HT2BR). MARY1 induces renal mitochondrial biogenesis (MB) and enhances renal mitochondrial function by increasing mitochondrial respiratory capacity, mitochondrial protein levels, and mitochondrial number in renal proximal tubular cells (RPTCs). MARY1 induces MB through 5-HT2BR and dual PI3K/AKT and RAS/MEK/ERK cell signaling pathways in RPTCs. MARY1 can be used to study renal diseases associated with metabolic and mitochondrial dysfunction .
    MARY1
  • HY-174858
    dASK1-VHL

    		PROTACs ASK1 p38 MAPK Metabolic Disease
    dASK1-VHL is an orally active PROTAC degrader targeting ASK1. dASK1-VHL can effectively bind VHL and promote the selective degradation of ASK1. dASK1-VHL effectively reduces ASK1 protein levels, inhibits the activation of p38 MAPK, and reduces liver lipid content. dASK1-VHL provides new ideas for the study of Metabolic dysfunction-associated steatohepatitis (MASH) (Pink: ASK1 ligand 1 (HY-174860); Blue: E3 ligand (S,R,S)-AHPC (HY-125845); Black: Linker, (S,R,S)-AHPC-CO-C2-PEG-NHCO-C2-COOH (HY-174861) .
    dASK1-VHL

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: